Adia Nutrition (ADIA) Non-Current Debt (2024 - 2025)
Adia Nutrition's (ADIA) quarterly Non-Current Debt came in at $600000.0 in Q4 2025, up 62.81% year-over-year from $368529.0 in Q4 2024, and up 62.81% quarter-over-quarter from $368529.0 in Q4 2024.
Powered by 
Analysis
Adia Nutrition (ADIA) Non-Current Debt (2024 - 2025) Analysis & Trends
Adia Nutrition (ADIA) has reported Non-Current Debt for 2 consecutive years, with $600000.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Non-Current Debt rose 62.81% year-over-year to $600000.0 in Q4 2025; TTM through Dec 2025 was $600000.0, a 62.81% increase from a year earlier, with the FY2025 full-year figure at $600000.0, up 62.81% from the prior year.
- Non-Current Debt was $600000.0 for Q4 2025 at Adia Nutrition, up from $368529.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $600000.0 in Q4 2025 and troughed at $368529.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 9.96 Bn | 9.12 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.47 Bn | 5.47 Bn | - | 586.20 Mn |
| 3 | Iovance Biotherapeutics | 4.64 Bn | 4.35 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.25 Bn | 2.28 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 50.15 Mn |
| 6 | Precigen | 2.79 Bn | 2.79 Bn | 52.17 Mn | 93.88 Mn |
| 7 | Beam Therapeutics | 2.58 Bn | 2.58 Bn | - | 100.26 Mn |
| 8 | Sarepta Therapeutics | 2.12 Bn | 1.33 Bn | 251.87 Mn | 847.62 Mn |
| 9 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | - |
| 10 | Adia Nutrition | 11.33 Mn | 11.33 Mn | - | - |